Seeking Alpha

Perrigo Company (PRGO)

  • Yesterday, 9:58 AM
    • Under Irish Takeover Rules, Mylan (MYL +1%) issues a Rule 2.4 announcement setting forth its legally-binding commitment to acquire Perrigo (PRGO -1.8%) for $205 in cash and stock. Under the terms of the offer, PRGO shareholders will receive US$60 in cash plus 2.2 ordinary shares of MYL for each PRGO share.
    • The cash portion will be financed by a new bridge credit facility arranged by Goldman Sachs.
    • Perrigo's Board of Directors rejected Mylan's bid several days ago.
    • Previously: Perrigo unanimously rejects Mylan bid (April 21)
    • Previously: Mylan preparing new bid for Perrigo (April 22)
  • Wed, Apr. 22, 9:47 AM
    • According to CNBC, Mylan (MYL -0.7%) is planning to submit a revised bid for Perrigo (PRGO +2.3%) that will include a financing commitment.
    • Related ticker: (TEVA -1.3%)
  • Tue, Apr. 21, 5:53 PM
  • Tue, Apr. 21, 8:48 AM
    • 50% stock and 50% cash
    • The proposal gives Mylan (NASDAQ:MYL) shareholders a 37.7% premium to the stock price of Mylan on April 7, 2015, the last day of trading prior to Mylan's press release regarding its unsolicited proposal for Perrigo (NYSE:PRGO), and a 48.3% premium to the unaffected stock price of Mylan on March 10, 2015, which is the last day of trading prior to widespread speculation of a transaction between Teva (NYSE:TEVA) and Mylan.
    • Expected to be significantly accretive to Teva non-GAAP EPS, starting in the mid-teens in year 1 and approaching 30% by year 3.
    • Teva/Mylan product offerings would create a combined pipeline of over 400 pending ANDAs and over 80 first-to-files in the U.S.
    • MYL +9.3% premarket to $74.40. TEVA +2.8% premarket.
    • Source: Press Release
    • Previously: Bloomberg: Teva offer for Mylan could come today (Apr. 21)
    • Previously: Mylan says rumored Teva marriage would not makes sense (Apr. 20)
    • Related: Why Does Mylan Want To Buy Perrigo? (Apr. 9)
  • Mon, Apr. 20, 11:20 AM
    • Generics firm Mylan (MYL -2.9%) admits that it considered a merger with Teva Pharmaceuticals Industries (TEVA -1.4%) but such a deal would be "without sound industrial logic." CEO Robert Coury says, "We believe that it is unlikely that any such combination could obtain antitrust regulatory clearances. Mylan is fully committed to its stand-alone strategy, including its proposal to acquire Perrigo, and today's speculation has no impact whatsoever on this strategy."
    • Many observers believe that Mylan's unsolicited $29B bid for Perrigo (PRGO -0.7%) was a defensive tactic to make itself less attractive to Teva.
    • Teva has not disclosed its intentions as of yet.
    • Previously: Teva reportedly weighing bid for Mylan; shares jump (April 17)
    | Comment!
  • Fri, Apr. 17, 2:30 PM
    • The WSJ and Bloomberg report Teva (TEVA +3.4%) is weighing a bid to acquire fellow generic drug giant Mylan (MYL +5.5%), while adding no decision has been made yet. Shaes of both companies have spiked higher.
    • Bloomberg's sources state Teva "hasn't made a formal approach yet," though Mylan is aware of Teva's interest. Many analysts have long expected Teva to go after Mylan, given many perceived top and bottom-line synergies. Teva is currently worth $66.2B, and Mylan $34.3B.
    • Perrigo (PRGO -2.8%), which Mylan announced a $28.9B ($205/share) bid for last week, has moved lower on the news.
  • Wed, Apr. 8, 11:47 AM
    • Mylan (MYL +10.4%) submits a non-binding proposal to Perrigo (PRGO +27.6%) to acquire it for $205 per share in a cash-and-stock deal. If consummated, the combined company would generate over $15B in annual sales.
    • Generic drug-related tickers: (LCI +3%)(AKRX +4.4%)(MNK +2.8%)(IPXL +2.3%)(TARO +2.3%)(TEVA +3.2%)
  • Nov. 25, 2014, 3:56 PM
    • Perrigo Company plc (PRGO -0.1%) places $1.6B aggregate principal amount of Senior Notes. The offering consisted of $500M 3.50% Senior Notes due 2021, $700M 3.90% Senior Notes due 2024 and $400M 4.90% Senior Notes due 2044. The three issues were sold at 99.937%, 99.579% and 99.701%, respectively.
    • Proceeds will fund the company's acquisition of Omega Pharma Invest NV.
    | Comment!
  • Nov. 6, 2014, 7:44 AM
    • Perrigo Co. (NYSE:PRGO) acquires Belgian consumer health products maker Omega Pharma NV for €2.48B ($3.11B) plus €1.1B in debt. 
    • The company will finance the transaction with a combination of cash and debt. It will play 25% of the equity value via the placement of shares to Omega founder Marc Coucke.
    | Comment!
  • Oct. 30, 2014, 9:36 AM
    • Bloomberg reports Perrigo (PRGO +1.2%) is in "exclusive talks" to buy Belgian over-the-counter drugmaker Omega Pharma, and that a deal could be reached soon.
    • Omega was previously reported to be on the block back in August. Bloomberg's sources state the company could be sold for over €4B ($5B).
    | 1 Comment
  • Sep. 29, 2014, 3:57 PM
    • Perrigo Co. (PRGO -0.6%) acquires a portfolio of women's healthcare products from privately-held Missouri-based Lumara Health for $82M in cash. The products generated more than $15M in top-line sales for the 12-month period ended March 31, 2014.
    • Separately, Perrigo transfers a portfolio of preclinical research assets to Imago Pharmaceuticals for an undisclosed upfront payment, development-related milestones and royalties on future sales. The portfolio includes IP, drug candidates and a 500k compound CNS-focused small molecule library. It acquired the assets when it bought Elan Corp. in December 2013.
    | Comment!
  • Aug. 29, 2014, 9:05 AM
    • People familiar with the situation say that the Belgian OTC drug maker Omega Pharma NV has attracted interest from a number of pharmaceutical companies including Perrigo (NYSE:PRGO), Boehringer Ingelheim, Bayer (OTCPK:BAYZF) (OTCPK:BAYRY) and Sanofi (NYSE:SNY) (OTCQB:SNYNF).
    • The tab for acquiring the business could be as high as 4B euros ($5.3B).
    | 1 Comment
  • Jul. 21, 2014, 7:15 AM
    • Bloomberg reports that, according to analysts, there are three ex-U.S. medical firms that should be high on the target acquisition list for tax inversion deals. Ireland-based Perrigo (NYSE:PRGO), Switzerland-based Actelion and U.K.-based Smith & Nephew Plc (NYSE:SNN) (OTCQB:SNNUF) are all attractive targets. Observers believe there will be more acquisitions consummated before Congress puts limits on the maneuvers.
    • Stryker (NYSE:SYK) has been mentioned as a potential suitor for Smith& Nephew. Pfizer (NYSE:PFE) may make another run at AstraZeneca (NYSE:AZN) after the end of the cool-off period.
    | 1 Comment
  • Nov. 18, 2013, 7:11 AM
    • Elan's (ELN) shareholders have authorized the $8.6B sale of the company to Perrigo (PRGO), clearing the way for the firms to complete the transaction by the end of 2013.
    • Perrigo will gain an Irish HQ, and so will enjoy lower taxes, as well as royalties from blockbuster multiple sclerosis drug Tysabri.
    | Comment!
  • Aug. 5, 2013, 1:00 PM
    • Perrigo's (PRGO) recent deal for Elan has investors all jazzed up about Irish-domiciled healthcare companies.
    • The allure of a 12.5% corporate tax rate could mean more M&A activity in the not-so-distant future for "anything with an Irish corporate tax structure," one analyst tells Bloomberg.
    • Some of the names being tossed about: Jazz Pharmaceuticals (JAZZ +3.2%) and Alkermes (ALKS +3.8%).
    | Comment!
  • Jul. 30, 2013, 1:42 PM
    • The sell-side likes Perrigo's (PRGO +0.5%) acquisition of Elan.
    • Deutsche upgrades the shares to Buy from Hold (PT to $150 from $120), saying the deal "makes sense for a number of reasons," and noting that $125 "looks like an attractive entry point."
    • Goldman ups the stock to Neutral from Sell (PT to $132 from $122) as Jami Rubin says the acquisition "provides PRGO a more flexible financial structure ... to drive enhanced ROIC from future deal activity."
    • Stifel raises its price target to $145 from $125 and BofA upgrades the shares to Neutral (PT to $133 from $116) citing "significant tax (and operational) synergies."
    | Comment!
Visit Seeking Alpha's
PRGO vs. ETF Alternatives
Company Description
Perrigo Co PLC develops, manufactures and distributes over-the-counter and generic prescription pharmaceuticals, nutritional products and active pharmaceutical ingredients.